Pinnacle Financial Partners Inc Acquires 84 Shares of Stryker Co. (NYSE:SYK)

Pinnacle Financial Partners Inc increased its holdings in Stryker Co. (NYSE:SYK) by 1.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,795 shares of the medical technology company’s stock after purchasing an additional 84 shares during the quarter. Pinnacle Financial Partners Inc’s holdings in Stryker were worth $2,447,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the business. Callan Capital LLC boosted its position in Stryker by 6.1% during the 4th quarter. Callan Capital LLC now owns 701 shares of the medical technology company’s stock valued at $252,000 after acquiring an additional 40 shares in the last quarter. Dividend Assets Capital LLC boosted its position in Stryker by 4.0% during the 4th quarter. Dividend Assets Capital LLC now owns 29,093 shares of the medical technology company’s stock valued at $10,475,000 after acquiring an additional 1,124 shares in the last quarter. Transcend Capital Advisors LLC boosted its position in Stryker by 11.5% during the 4th quarter. Transcend Capital Advisors LLC now owns 10,942 shares of the medical technology company’s stock valued at $3,940,000 after acquiring an additional 1,132 shares in the last quarter. Bradley Foster & Sargent Inc. CT boosted its position in Stryker by 2.9% during the 4th quarter. Bradley Foster & Sargent Inc. CT now owns 60,329 shares of the medical technology company’s stock valued at $21,721,000 after acquiring an additional 1,679 shares in the last quarter. Finally, Paradigm Asset Management Co. LLC bought a new stake in Stryker during the 4th quarter valued at approximately $1,188,000. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

Shares of NYSE SYK opened at $382.59 on Friday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The firm has a market cap of $145.99 billion, a P/E ratio of 49.30, a PEG ratio of 2.93 and a beta of 0.96. The company has a 50 day moving average of $378.07 and a 200 day moving average of $368.99. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 earnings per share. As a group, research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on SYK shares. Argus set a $450.00 price objective on Stryker in a research report on Monday, February 3rd. BTIG Research lifted their price objective on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price objective on shares of Stryker in a research report on Wednesday, January 29th. Robert W. Baird lifted their target price on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, Truist Financial lifted their target price on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.